Arcus Biosciences Inc (RCUS)
Activity ratios
Short-term
Turnover ratios
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Inventory turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Receivables turnover | 51.60 | 52.60 | 49.40 | 47.40 | 29.25 | 29.84 | 3.46 | 3.31 | 2.60 | 14.47 | 10.50 | 12.47 | 0.53 | 18.91 | 39.78 | 15.61 | 48.69 | 209.09 | 62.76 | — |
Payables turnover | 8.11 | 11.31 | 9.80 | 9.06 | 7.18 | 7.02 | 9.64 | 4.05 | 5.35 | 9.68 | 4.19 | 4.60 | 7.43 | 4.79 | 3.43 | 2.15 | 2.81 | 4.68 | 2.93 | 12.60 |
Working capital turnover | 0.33 | 0.29 | 0.30 | 0.28 | 0.18 | 0.18 | 0.15 | 0.14 | 0.13 | 0.47 | 0.38 | 0.36 | 0.36 | 0.13 | 0.18 | 0.13 | 0.13 | 0.12 | 0.03 | 0.10 |
The analysis of Arcus Biosciences Inc's activity ratios reveals important insights into the efficiency of the company's operations.
1. Inventory Turnover: The inventory turnover ratio indicates how often the company's inventory is sold and replaced over a specific period. Unfortunately, the data for Arcus Biosciences Inc's inventory turnover is missing or not available.
2. Receivables Turnover: This ratio measures how quickly the company collects payments from its customers. Arcus Biosciences Inc's receivables turnover fluctuated over the years, with a significant decrease in the turnover for the period ending in December 2021 but showing improvements in subsequent periods, reaching a relatively stable level by December 2024.
3. Payables Turnover: The payables turnover ratio reflects the efficiency of the company in paying its suppliers. Arcus Biosciences Inc's payables turnover increased steadily from March 2020 to December 2024, indicating improved efficiency in paying its suppliers.
4. Working Capital Turnover: This ratio assesses how effectively the company utilizes its working capital to generate sales. Arcus Biosciences Inc's working capital turnover varied over the years, with a notable increase in December 2021 followed by fluctuations before stabilizing at a relatively higher level by December 2024, suggesting better utilization of working capital in generating sales.
Overall, while the specific analysis of inventory turnover is not available, the evaluation of receivables turnover, payables turnover, and working capital turnover reflects varying levels of operational efficiency and working capital management by Arcus Biosciences Inc during the analyzed periods.
Average number of days
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Days of inventory on hand (DOH) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Days of sales outstanding (DSO) | days | 7.07 | 6.94 | 7.39 | 7.70 | 12.48 | 12.23 | 105.37 | 110.42 | 140.13 | 25.23 | 34.75 | 29.27 | 684.32 | 19.30 | 9.18 | 23.38 | 7.50 | 1.75 | 5.82 | — |
Number of days of payables | days | 45.00 | 32.28 | 37.24 | 40.28 | 50.86 | 51.98 | 37.87 | 90.04 | 68.27 | 37.69 | 87.06 | 79.42 | 49.09 | 76.16 | 106.37 | 169.69 | 130.02 | 78.01 | 124.66 | 28.97 |
The activity ratios of Arcus Biosciences Inc provide insights into the company's efficiency in managing its operations.
1. Days of Inventory on Hand (DOH): The DOH metric indicates the average number of days it takes for the company to sell its inventory. However, the data provided shows "— days" for all the periods, suggesting that inventory turnover information is not available.
2. Days of Sales Outstanding (DSO): DSO measures the average number of days it takes for the company to collect payments from its customers after making a sale. The DSO data varies significantly over the periods, with a high of 684.32 days on December 31, 2021, indicating potential issues with accounts receivable collection efficiency. Overall, the DSO values have fluctuated, which may indicate evolving credit policies or changes in customer payment behavior.
3. Number of Days of Payables: This ratio demonstrates how long the company takes to pay its suppliers. The number of days of payables has also exhibited variability over time. A decreasing trend can be observed from 2020 to 2022, indicating a potential improvement in the company's supplier payment management. However, there was a slight increase in days of payables from September 30, 2022, to December 31, 2024, which could be due to changing payment terms or supplier relationships.
In conclusion, while the data limitations for DOH make it challenging to assess inventory management, fluctuations in DSO and days of payables highlight the importance of monitoring and optimizing working capital cycles to enhance operational efficiency and overall financial performance.
Long-term
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fixed asset turnover | 5.49 | 5.48 | 5.04 | 4.65 | 2.29 | 2.39 | 2.69 | 3.22 | 3.20 | 12.78 | 12.23 | 11.92 | 12.45 | 1.85 | 4.55 | 6.26 | 7.17 | 8.91 | 1.82 | 1.71 |
Total asset turnover | 0.22 | 0.21 | 0.21 | 0.18 | 0.11 | 0.10 | 0.10 | 0.09 | 0.08 | 0.31 | 0.28 | 0.26 | 0.25 | 0.06 | 0.12 | 0.10 | 0.10 | 0.10 | 0.03 | 0.09 |
The Fixed Asset Turnover ratio of Arcus Biosciences Inc has shown fluctuations over the observed period. The ratio started at 1.71 in March 2020, showing an improving trend until reaching a peak of 12.78 in September 2022, reflecting efficient utilization of fixed assets. However, the ratio declined significantly thereafter, standing at 5.49 in December 2024. Despite the decrease in the later periods, Arcus Biosciences Inc generally demonstrated effective management of fixed assets to generate sales during the period under review.
On the other hand, the Total Asset Turnover ratio depicts a different trend. It started low at 0.09 in March 2020 and gradually increased to 0.31 by September 2022 before declining to 0.22 in December 2024. This indicates that the company's ability to generate sales from its total assets also improved over time, reaching its peak efficiency in September 2022, but then experienced a slight decline towards the end of the observed period.
Overall, the assessment of Arcus Biosciences Inc's long-term activity ratios suggests that the company displayed effectiveness in generating sales relative to its fixed and total assets, although there were fluctuations in performance over the analyzed timeframe.